Annual report
9987.TEDINET S100YFRU
Period2025-04-01 → 2026-03-31
Filed2026-06-22
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.49T | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥2.40T | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥2.39T | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.31T | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.24T | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Operating income | ¥36.4bn | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥37.1bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥39.7bn | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥38.8bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥38.4bn | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥36.4bn | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥23.4bn | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥54.3bn | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥50.3bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥38.1bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥34.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥29.0bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥20.3bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥14.4bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥38.1bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥34.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥1.16T | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥1.11T | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥1.23T | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.15T | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.14T | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥739.8bn | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥706.4bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥416.0bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥407.4bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥416.4bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥411.5bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥418.1bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥116.7bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥102.7bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥131.6bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥118.6bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥198.7bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥132.9bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥168.2bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥33.6bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥65.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥87.2bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥37.3bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥9.5bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥12.8bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥20.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥10.3bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥46.4bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥1.4bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥33.3bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥35.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥31.7bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥26.2bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥11.6bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥545.54 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥454.58 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥357.88 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥236.47 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥163.19 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥6,148.58 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥5,651.56 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥5,361.96 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,970.38 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,749.59 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 36.0% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.6% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.9% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.9% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.6% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 9.3% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.4% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.0% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.9% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.4% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 12,717 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 12,923 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 13,086 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 13,429 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 14,032 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥2.30T | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥2.21T | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥2.19T | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.12T | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.04T | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | ¥22.7bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥23.9bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥28.2bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥28.8bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥28.5bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥24.7bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥14.9bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥40.0bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥36.9bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥29.2bn | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥25.7bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥21.1bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥14.9bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥13.8bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.04T | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥1.02T | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥1.13T | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.05T | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.03T | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥770.9bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥749.6bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥269.2bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥271.6bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥286.6bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥290.8bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥302.5bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥79.2bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥61.1bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥418.27 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥339.09 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥259.73 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥172.97 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥156.55 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥100 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥100 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥80 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥72 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥72 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥3,979.89 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,768.25 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,691.98 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,515 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,440.25 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 25.9% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 26.6% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 25.3% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 27.7% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.5% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 10.8% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.2% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.0% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.6% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 72,167,000 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 72,167,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 77,740,000 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 82,831,000 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 103,344,000 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 2,991 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 3,082 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 3,176 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 3,232 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 3,430 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 90
| Segment | Item | Period | Value |
|---|---|---|---|
| The Community Healthcare And Nursing Care Support Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥658m |
| The Community Healthcare And Nursing Care Support Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥735m |
| The Community Healthcare And Nursing Care Support Businessreportable segment | employees | at 2026-03-31 | 3322 pure |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥93.9bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥93.9bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥14m |
| The Community Healthcare And Nursing Care Support Businessreportable segment | segment assets | at 2026-03-31 | ¥42.3bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥1.5bn |
| The Healthcare Product Development Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥1.4bn |
| The Healthcare Product Development Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥671m |
| The Healthcare Product Development Businessreportable segment | employees | at 2026-03-31 | 861 pure |
| The Healthcare Product Development Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥51.6bn |
| The Healthcare Product Development Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥11.9bn |
| The Healthcare Product Development Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥39.7bn |
| The Healthcare Product Development Businessreportable segment | segment assets | at 2026-03-31 | ¥67.8bn |
| The Healthcare Product Development Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥830m |
| The Healthcare Related Services Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥201m |
| The Healthcare Related Services Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥520m |
| The Healthcare Related Services Businessreportable segment | employees | at 2026-03-31 | 688 pure |
| The Healthcare Related Services Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥43.0bn |
| The Healthcare Related Services Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥24.6bn |
| The Healthcare Related Services Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥18.3bn |
| The Healthcare Related Services Businessreportable segment | segment assets | at 2026-03-31 | ¥38.0bn |
| The Healthcare Related Services Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥1.3bn |
| The Pharmaceutical Distribution Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥17.3bn |
| The Pharmaceutical Distribution Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥10.4bn |
| The Pharmaceutical Distribution Businessreportable segment | employees | at 2026-03-31 | 7834 pure |
| The Pharmaceutical Distribution Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥2.40T |
| The Pharmaceutical Distribution Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥2.35T |
| The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥51.6bn |
| The Pharmaceutical Distribution Businessreportable segment | segment assets | at 2026-03-31 | ¥1.04T |
| The Pharmaceutical Distribution Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥31.5bn |
| The Specialty Drug Contract Distribution Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥17m |
| The Specialty Drug Contract Distribution Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥12m |
| The Specialty Drug Contract Distribution Businessreportable segment | employees | at 2026-03-31 | 12 pure |
| The Specialty Drug Contract Distribution Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥436.1bn |
| The Specialty Drug Contract Distribution Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥6.8bn |
| The Specialty Drug Contract Distribution Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥429.3bn |
| The Specialty Drug Contract Distribution Businessreportable segment | segment assets | at 2026-03-31 | ¥93.3bn |
| The Specialty Drug Contract Distribution Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥1.2bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2025-04-01 → 2026-03-31 | ¥19.5bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-04-01 → 2026-03-31 | ¥12.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2026-03-31 | ¥3.03T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2026-03-31 | ¥2.49T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥539.0bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2026-03-31 | ¥1.28T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2026-03-31 | ¥36.3bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥970m |
| The Community Healthcare And Nursing Care Support Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥803m |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥94.4bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥94.4bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥15m |
| The Community Healthcare And Nursing Care Support Businessreportable segment | segment assets | at 2025-03-31 | ¥41.5bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.3bn |
| The Healthcare Product Development Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥800m |
| The Healthcare Product Development Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥509m |
| The Healthcare Product Development Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥52.6bn |
| The Healthcare Product Development Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥11.7bn |
| The Healthcare Product Development Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥40.9bn |
| The Healthcare Product Development Businessreportable segment | segment assets | at 2025-03-31 | ¥66.0bn |
| The Healthcare Product Development Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.9bn |
| The Healthcare Related Services Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥311m |
| The Healthcare Related Services Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥501m |
| The Healthcare Related Services Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥42.2bn |
| The Healthcare Related Services Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥24.3bn |
| The Healthcare Related Services Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥17.9bn |
| The Healthcare Related Services Businessreportable segment | segment assets | at 2025-03-31 | ¥33.0bn |
| The Healthcare Related Services Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.0bn |
| The Pharmaceutical Distribution Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥18.8bn |
| The Pharmaceutical Distribution Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥10.2bn |
| The Pharmaceutical Distribution Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥2.31T |
| The Pharmaceutical Distribution Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥2.26T |
| The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥50.8bn |
| The Pharmaceutical Distribution Businessreportable segment | segment assets | at 2025-03-31 | ¥987.0bn |
| The Pharmaceutical Distribution Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥31.9bn |
| The Specialty Drug Contract Distribution Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥6m |
| The Specialty Drug Contract Distribution Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥10m |
| The Specialty Drug Contract Distribution Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥295.5bn |
| The Specialty Drug Contract Distribution Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥6.4bn |
| The Specialty Drug Contract Distribution Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥289.1bn |
| The Specialty Drug Contract Distribution Businessreportable segment | segment assets | at 2025-03-31 | ¥58.2bn |
| The Specialty Drug Contract Distribution Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥845m |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥20.9bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥12.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥2.80T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥2.40T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥398.7bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥1.19T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥37.0bn |
| The Pharmaceutical Distribution Businessreportable segment | employees | at 2026-03-31 | 2991 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,132
| Item | Context | Value | Unit |
|---|---|---|---|
| Dividend per share dividends of surplus | FilingDateInstant_Row1Member | 50.00 | |
| Total amount of dividends dividends of surplus | FilingDateInstant_Row2Member | 3381000000 | JPY |
| Dividend per share dividends of surplus | FilingDateInstant_Row2Member | 50.00 | |
| Number of male directors and other officers | FilingDateInstant | 7 | |
| Number of female directors and other officers | FilingDateInstant | 3 | |
| Ratio of female directors and other officers | FilingDateInstant | 0.300 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02780-000AsanoShigeruMember | 35000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02780-000MiyataHiromiMember | 46000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02780-000TanakaHirohumiMember | 20000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02780-000TakahasiTieMember | 13000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02780-000SamuraSyunitiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02780-000NakagakiHideakiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02780-000TomitaAsakoMember | 7000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02780-000OgasawaraTakeshiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02780-000KondoTosimitiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02780-000SimizuAyakoMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant | 123000 | |
| Number of male directors and other officers proposal | FilingDateInstant | 7 | |
| Number of female directors and other officers proposal | FilingDateInstant | 3 | |
| Ratio of female directors and other officers proposal | FilingDateInstant | 0.300 | |
| Number of shares held ordinary shares information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E02780-000AsanoShigeruMember | 35000 | |
| Number of shares held ordinary shares information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E02780-000MiyataHiromiMember | 46000 | |
| Number of shares held ordinary shares information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E02780-000TanakaHirohumiMember | 20000 | |
| Number of shares held ordinary shares information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E02780-000TakahasiTieMember | 13000 | |
| Number of shares held ordinary shares information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E02780-000NakagakiHideakiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E02780-000OhnoTomohikoMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E02780-000TomitaAsakoMember | 7000 | |
| Number of shares held ordinary shares information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E02780-000OgasawaraTakeshiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E02780-000KondoTosimitiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E02780-000SimizuAyakoMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors proposal | FilingDateInstant | 123000 | |
| Audit fees reporting company | Prior1YearDuration | 93000000 | JPY |
| Non audit fees reporting company | Prior1YearDuration | － | JPY |
| Audit fees reporting company | CurrentYearDuration | 103000000 | JPY |
| Non audit fees reporting company | CurrentYearDuration | 6000000 | JPY |
| Audit fees consolidated subsidiaries | Prior1YearDuration | 64000000 | JPY |
| Non audit fees consolidated subsidiaries | Prior1YearDuration | 0 | JPY |
| Audit fees consolidated subsidiaries | CurrentYearDuration | 71000000 | JPY |
| Non audit fees consolidated subsidiaries | CurrentYearDuration | － | JPY |
| Audit fees total | Prior1YearDuration | 157000000 | JPY |
| Non audit fees total | Prior1YearDuration | 0 | JPY |
| Audit fees total | CurrentYearDuration | 174000000 | JPY |
| Non audit fees total | CurrentYearDuration | 6000000 | JPY |
| Audit fees reporting company network firms | Prior1YearDuration | － | JPY |
| Non audit fees reporting company network firms | Prior1YearDuration | 26000000 | JPY |
| Audit fees reporting company network firms | CurrentYearDuration | － | JPY |
| Non audit fees reporting company network firms | CurrentYearDuration | 94000000 | JPY |
| Audit fees consolidated subsidiaries network firms | Prior1YearDuration | － | JPY |
| Non audit fees consolidated subsidiaries network firms | Prior1YearDuration | 3000000 | JPY |
| Audit fees consolidated subsidiaries network firms | CurrentYearDuration | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |